Development of Extramusculoskeletal Manifestations in Upadacitinib‐Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis
In patients with spondyloarthritis, development of EMMs was generally low with upadacitinib 15 mg. Uveitis was numerically lower in patients treated with upadacitinib 15 mg versus placebo, and particularly in r-axSpA. Regardless of treatment in r-axSpA, having a history of uveitis appeared to predispose patients for future uveitis events.
Authors
- Ivan Lagunes
- Michael Paley (ORCID: https://orcid.org/0000-0001-8724-3176)
- Priscila Nakasato (ORCID: https://orcid.org/0000-0001-6709-1363)
- Denis Poddubnyy (ORCID: https://orcid.org/0000-0002-4537-6015)
- B. Parikh
- Stefan Siebert (ORCID: https://orcid.org/0000-0002-1802-7311)
- Victoria Navarro‐Compán (ORCID: https://orcid.org/0000-0002-4527-852X)
- Peter Wung (ORCID: https://orcid.org/0000-0002-1883-2097)
- Ana Biljan
- Ennio Lubrano (ORCID: https://orcid.org/0000-0001-6189-5328)
- Dirk Sw Elewaut (ORCID: https://orcid.org/0000-0002-7468-974X)
- Derek Coombs
Institutions
- University of Molise (IT)
- University Health Network (CA)
- University of Toronto (CA)
- Washington University in St. Louis (US)
- Hospital Universitario La Paz (ES)
- Ghent University Hospital (BE)
- AbbVie (United States) (US)
- VIB-UGent Center for Inflammation Research (BE)
- Charité - Universitätsmedizin Berlin (DE)
- University of Glasgow (GB)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1002/art.43069
- Citations
- 8
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.76